159 related articles for article (PubMed ID: 11444200)
1. k-ras mutation may be an early event in mucinous ovarian tumorigenesis.
Garrett AP; Lee KR; Colitti CR; Muto MG; Berkowitz RS; Mok SC
Int J Gynecol Pathol; 2001 Jul; 20(3):244-51. PubMed ID: 11444200
[TBL] [Abstract][Full Text] [Related]
2. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary.
Fujita M; Enomoto T; Inoue M; Tanizawa O; Ozaki M; Rice JM; Nomura T
Jpn J Cancer Res; 1994 Dec; 85(12):1247-56. PubMed ID: 7852189
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology.
Mandai M; Konishi I; Kuroda H; Komatsu T; Yamamoto S; Nanbu K; Matsushita K; Fukumoto M; Yamabe H; Mori T
Hum Pathol; 1998 Jan; 29(1):34-40. PubMed ID: 9445131
[TBL] [Abstract][Full Text] [Related]
4. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy.
Mok SC; Bell DA; Knapp RC; Fishbaugh PM; Welch WR; Muto MG; Berkowitz RS; Tsao SW
Cancer Res; 1993 Apr; 53(7):1489-92. PubMed ID: 8384077
[TBL] [Abstract][Full Text] [Related]
5. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases.
Cuatrecasas M; Villanueva A; Matias-Guiu X; Prat J
Cancer; 1997 Apr; 79(8):1581-6. PubMed ID: 9118042
[TBL] [Abstract][Full Text] [Related]
6. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors.
Ichikawa Y; Nishida M; Suzuki H; Yoshida S; Tsunoda H; Kubo T; Uchida K; Miwa M
Cancer Res; 1994 Jan; 54(1):33-5. PubMed ID: 8261457
[TBL] [Abstract][Full Text] [Related]
7. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary.
Enomoto T; Weghorst CM; Inoue M; Tanizawa O; Rice JM
Am J Pathol; 1991 Oct; 139(4):777-85. PubMed ID: 1656759
[TBL] [Abstract][Full Text] [Related]
8. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
[TBL] [Abstract][Full Text] [Related]
9. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
[TBL] [Abstract][Full Text] [Related]
10. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
11. K-RAS mutations in ovarian and extraovarian lesions of serous tumors of borderline malignancy.
Diebold J; Seemüller F; Löhrs U
Lab Invest; 2003 Feb; 83(2):251-8. PubMed ID: 12594239
[TBL] [Abstract][Full Text] [Related]
12. Immunophenotype and K-RAS mutation in mucinous ovarian adenocarcinoma with mural nodule of high-grade sarcoma: case report.
Desouki MM; Fadare O; Kanbour A; Kanbour-Shakir A
Int J Gynecol Pathol; 2014 Mar; 33(2):186-90. PubMed ID: 24487474
[TBL] [Abstract][Full Text] [Related]
13. Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations.
Hunter SM; Gorringe KL; Christie M; Rowley SM; Bowtell DD; ; Campbell IG
Clin Cancer Res; 2012 Oct; 18(19):5267-77. PubMed ID: 22891197
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneous genetic alterations in ovarian mucinous tumors: application and usefulness of laser capture microdissection.
Takeshima Y; Amatya VJ; Daimaru Y; Nakayori F; Nakano T; Inai K
Hum Pathol; 2001 Nov; 32(11):1203-8. PubMed ID: 11727259
[TBL] [Abstract][Full Text] [Related]
15. K-ras gene point mutations and p21ras immunostaining in human ovarian tumors.
Semczuk A; Postawski K; Przadka D; Rozynska K; Wrobel A; Korobowicz E
Eur J Gynaecol Oncol; 2004; 25(4):484-8. PubMed ID: 15285310
[TBL] [Abstract][Full Text] [Related]
16. Identical, unique p53 mutations in a primary ovarian mucinous adenocarcinoma and a synchronous contralateral ovarian mucinous tumor of low malignant potential suggest a common clonal origin.
Werness BA; DiCioccio RA; Piver MS
Hum Pathol; 1997 May; 28(5):626-30. PubMed ID: 9158713
[TBL] [Abstract][Full Text] [Related]
17. Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy.
Jimenez RE; Warshaw AL; Z'graggen K; Hartwig W; Taylor DZ; Compton CC; Fernández-del Castillo C
Ann Surg; 1999 Oct; 230(4):501-9; discussion 509-11. PubMed ID: 10522720
[TBL] [Abstract][Full Text] [Related]
18. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.
Gemignani ML; Schlaerth AC; Bogomolniy F; Barakat RR; Lin O; Soslow R; Venkatraman E; Boyd J
Gynecol Oncol; 2003 Aug; 90(2):378-81. PubMed ID: 12893203
[TBL] [Abstract][Full Text] [Related]
19. Synchronous mucinous tumors of the appendix and the ovary associated with pseudomyxoma peritonei. A clinicopathologic study of six cases with comparative analysis of c-Ki-ras mutations.
Cuatrecasas M; Matias-Guiu X; Prat J
Am J Surg Pathol; 1996 Jun; 20(6):739-46. PubMed ID: 8651354
[TBL] [Abstract][Full Text] [Related]
20. Detection and clinical correlations of ras gene mutations in human ovarian tumors.
Varras MN; Sourvinos G; Diakomanolis E; Koumantakis E; Flouris GA; Lekka-Katsouli J; Michalas S; Spandidos DA
Oncology; 1999; 56(2):89-96. PubMed ID: 9949292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
